Author details

Full Name

Bruce A C Cree

Affiliation

ORCID

Career Start Year

2002

Papers

211

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35253861	Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans.	Brain	2023
35975888	Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.	AJR Am J Roentgenol	2023
36093738	Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants.	Annals of Neurology	2023
37804003	Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.	Ann Clin Transl Neurol	2023
37550942	SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis.		2023
37769428	Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.		2023
37094998	Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.	Neurol Neuroimmunol Neuroinflamm	2023
37282545	Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.	Mult Scler	2023
37205595	A Predictive Autoantibody Signature in Multiple Sclerosis.	medRxiv	2023
37461671	Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosis.	medRxiv	2023
36573559	Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis.	Mult Scler	2023
37258412	International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.	Neurol Neuroimmunol Neuroinflamm	2023
37245350	Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.		2023
36997638	Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes.	Commun Biol	2023
37221052	Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.	J Neurol Neurosurg Psychiatry	2023
35284994	COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.	Neurology and Therapy	2022
35397292	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial.	Mult Scler Relat Disord	2022
35461057	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis.	Multiple Sclerosis and Related Disorders	2022
36370634	Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.	EBioMedicine	2022
36038272	Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.	Neurology	2022
35765217	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â¿¿years of follow-up in the DAYBREAK open-label extension trial.	Multiple Sclerosis Journal	2022
35503396	Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.	Neurology and Therapy	2022
35380078	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â¿¿years.	Multiple Sclerosis Journal	2022
36001711	Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.	N Engl J Med	2022
35936922	Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.	Multiple Sclerosis Journal - Experimental, Translational and Clinical	2022
35677343	Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis.	Front Neurol	2022
35674067	New drugs for multiple sclerosis: new treatment algorithms.	Current Opinion in Neurology	2022
36124839	All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes.	Multiple Sclerosis Journal	2022
35725892	The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.	CNS Drugs	2022
35779190	Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 ImmunoglobulinÂ G-positive Neuromyelitis Optica Spectrum Disorder".	Neurol Ther	2022
34240656	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.	Mult Scler	2022
35318259	Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series.	Neurol Neuroimmunol Neuroinflamm	2022
34405267	Identifying falls remotely in people with multiple sclerosis.	J Neurol	2022
35261318	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.	Multiple Sclerosis Journal	2022
35233827	Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS".	Ann Neurol	2022
35182500	Multiple sclerosis: two decades of progress.	Lancet Neurology, The	2022
35158465	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.	Mult Scler Relat Disord	2022
35158461	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.	Multiple Sclerosis and Related Disorders	2022
34878197	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.	Ann Neurol	2022
34911760	Specific hypomethylation programs underpin B cell activation in early multiple sclerosis.	Proc Natl Acad Sci U S A	2021
34292643	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.	European Journal of Neurology	2021
33538237	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.	Mult Scler	2021
33578191	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.	Mult Scler Relat Disord	2021
33892317	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.	Multiple Sclerosis and Related Disorders	2021
33842099	Effects of COVID-19 "Sheltering in Place" on Activity in People With Multiple Sclerosis.	Neurology: Clinical Practice	2021
33454584	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.	Multiple Sclerosis and Related Disorders	2021
34147885	Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies.	Multiple Sclerosis and Related Disorders	2021
33724534	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.	Annals of Neurology	2021
33771837	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.	Neurol Neuroimmunol Neuroinflamm	2021
33769117	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.	Mult Scler	2021